Incretin-based Therapy in Late Preclinical Type 1 Diabetes

Phase 2 Completed 13 enrolled University of Oulu Oulu University Hospital · collab Skane University Hospital · collab Tampere University Hospital · collab Turku University Hospital · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia.

Timeline

Start: 2016-03
Primary completion: 2021-06
Completion: 2021-06

Publications

Kero J, Koskenniemi JJ, Karsikas S, Pokka T, Lou O, Toppari J, Veijola R. INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA). Diabet Med. 2022 Oct;39(10):e14913. doi: 10.1111/dme.14913. Epub 2022 Jul 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Liraglutide	Peptide	1.8 mg	Subcutaneous

Incretin-based Therapy in Late Preclinical Type 1 Diabetes

Summary

Timeline

Publications

Drugs

Indications